Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotorasib vs Durvalumab in KRAS G12C Mutant LA-NSCLC with Persistent ctDNA MRD
NCT06333678Phase 2Terminated
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Mar 2024
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sotorasib in non-small cell lung cancer (NSCLC), sponsored by Memorial Sloan Kettering Cancer Center. Started Mar 2024; status: terminated.
02
Drugs
sotorasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06333678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06333678.